Skip to main content
Clinical Trials/NCT06339307
NCT06339307
Completed
Not Applicable

A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for Lymph Node Metastasis in Gastric Cancer Patients

Tianjin Medical University Cancer Institute and Hospital1 site in 1 country120 target enrollmentFebruary 15, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Predictive Cancer Model
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment
120
Locations
1
Primary Endpoint
lymph node metastasis
Status
Completed
Last Updated
7 months ago

Overview

Brief Summary

In our prior research, a risk scoring model for the occurrence of lymph node metastasis in patients who underwent radical gastrectomy for gastric cancer was established. To further validate this scoring model, a prospective study has been designed with the aim of prospectively assessing the model's clinical applicability.

Detailed Description

The study was a single-centre, prospective study. Data prospectively accrued were employed to evaluate the concordance between observed patient outcomes, with respect to lymph node metastasis status post-curative gastrectomy, and the prognostications tendered by the established risk scoring model, thereby appraising the model's clinical applicability and validity.

Registry
clinicaltrials.gov
Start Date
February 15, 2024
End Date
April 21, 2025
Last Updated
7 months ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Primary gastric adenocarcinoma;
  • Curative surgery (with R0 resection, excluding palliative surgery and cases with distant metastasis).

Exclusion Criteria

  • Patients with autoimmune diseases, inflammation, or hematological disorders;
  • Patients with a history of or concurrent other cancers;
  • Presence of active infection and inflammation (based on WBC count, patients with count of 10×10\^9 or higher should be evaluated through medical record examination for the presence of infection);
  • Active bleeding (as determined by endoscopic ultrasound and HGB ≤ 90);
  • Post neoadjuvant radiotherapy or chemotherapy;
  • History of blood transfusion, corticosteroid use, or leukocyte-stimulating medications within the past month prior to blood draw;
  • Incomplete clinical and pathological data.

Outcomes

Primary Outcomes

lymph node metastasis

Time Frame: 1 month after curative surgery

Collect postoperative pathological data from gastric cancer patients who have undergone curative gastrectomy to determine the occurrence of lymph node metastasis.

Study Sites (1)

Loading locations...

Similar Trials